ATAI Life Sciences N.V. - Ordinary Shares, par value Euro 0.10 per share (IGXT)

Q: What does CUSIP 45822R101 represent in this 13F holders report?

CUSIP 45822R101 is the security identifier for IGXT - ATAI Life Sciences N.V. - Ordinary Shares, par value Euro 0.10 per share used to aggregate holder disclosures.

Q: How many institutions held IGXT - ATAI Life Sciences N.V. - Ordinary Shares, par value Euro 0.10 per share in Q1 2024?

1 institutional investor reported IGXT - ATAI Life Sciences N.V. - Ordinary Shares, par value Euro 0.10 per share for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 45822R101

Q1 2024 13F Holders as of 31 Mar 2024

Security type / class: Equity / Ordinary Shares, par value Euro 0.10 per share
Total 13F shares: 2,300
Total 13F value: $414
Share change: +2,300
SEC-reported price per share: $0.18
Number of holders: 1
Value change: +$414
Number of buys: 1
Shares outstanding: 235,630,746

Security key

45822R101

Report period

Q1 2024

Institutions

Top holders

IGXT full security history Ownership snapshot Full 13F holder table Atai Beckley N.V. SEC filings Atai Beckley N.V. company facts Atai Beckley N.V. 13D/G history

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of IGXT - ATAI Life Sciences N.V. - Ordinary Shares, par value Euro 0.10 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Stephen Bardin

Disclosed value leader

—

Comparable rows

0/5

Latest evidence

23 May 2023

3/4/5 Some rows are evidence-backed but not safely comparable across classes. 5 rows are not safely comparable across share classes.

Quick read

SEC ownership evidence is available, but the rows are not safely comparable across share classes.

0 of 5 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Stephen Bardin's linked filing trail.

Detailed SEC evidence table Showing 1-5 of 5 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Stephen Bardin	3/4/5 Chief Financial Officer 3/4/5	— mixed-class rows	— 950,000 shares mixed-class rows	—	14 Mar 2023
Rolando Gutierrez-Esteinou	3/4/5 Chief Medical Officer 3/4/5	— mixed-class rows	— 700,000 shares mixed-class rows	—	14 Mar 2023
Gregory L. Weaver	3/4/5 Chief Financial Officer 3/4/5	— denominator unverified	— 228,000 shares	—	02 Mar 2022
Alexis de Rosnay	3/4/5 Director 3/4/5	— denominator unverified	— 64,000 shares	—	25 May 2022
Jason Camm	3/4/5 Director 3/4/5	— denominator unverified	— 64,000 shares	—	23 May 2023

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

2,300

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2024 vs Q1 2024 Across Filers

Q1 2024 holders

Holder diff

Investor	Q1 2024 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q1 2024 value	Q1 2024 value	Value change	Value Chg %